Research Acceptances
Get in Touch
Ontada
June 3-7
Chicago, IL
Booth 17160
The development of analytic technologies has made the design and execution of complex studies more possible. Applications in the oncology space continue to grow, but complete, reliable and representative data is hard to come by.
Complex research is critical in the effort to move cancer care forward. With our unique connection to The US Oncology Network, one of the largest networks of independent, physician-owned community practices, we are well positioned to conduct meaningful complex research that uncovers deeper patient insights and perspectives that advance cancer care.
MYLUNG
Consortium
The US Oncology Network
Ontada at a glance
Let's Connect.
Whether you’re focused on capturing unique data to power provider engagement or are looking to real-world evidence to catalyze groundbreaking research, we can help you meet your goals and achieve the best patient outcomes.
© 2022 Ontada, LLC
Get in Touch
Ontada
Beth Koselke, PharmD, BCOP
Learn more >
Learn More
Research Acceptances
ASCO 2022
Meet our lead researchers
Real-World Policy Perspective
Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products (FDA-2021-D-1214)
Data Standards for Drug and Biological Submissions Containing Real- World-Data: Guidance for Industry (FDA-2021-D-0548)
Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products Guidance for Industry (FDA-2021-D-1146)
Re: Real-World Data: Assessing Electronic Health Records (EHRs) and Medical Claims Data to Support Regulatory Decision-Making for Drugs and Biological Products (FDA-2020-D-2307)
TM
Beth Koselke, PharmD, BCOP
Sr. Clinical Pharmacist
Expertise
Beth Koselke, PharmD, BCOP is a board-certified oncology clinical pharmacist with extensive experience based in community oncology practices. Her proficiencies include efficient chemotherapy regimen review ensuring safe, appropriate, and personalized medication delivery to oncology patients.
Education & Experience
Beth graduated from Purdue University with a doctorate in pharmacy. She then completed a PGY1 pharmacy practice and PGY2 hematology/oncology residency at the University of Michigan. She spent eight years as a clinical oncology and precision genomics pharmacist prior to joining the US Oncology Pharmacy ClinReview team as a Senior Oncology Pharmacist.
Learn more >
Philip K. Chan, PhD, MS
Learn more >
Lavanya Sudharsan
Learn more >
Alisha Monnette, PhD, MPH
Blood Monocyte and Lymphocyte Counts Versus Patient Outcomes in Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitor Therapy: Real-World Data of 12,416 pts.
Characteristics, Blood Counts, Treatments, and Clinical Outcomes of 3022 Patients (Pts) With Polycythemia Vera (PV) Treated in US Community Practices
Lavanya Sudharsan, MS
Real-World Progression-Free and Overall Survival for Patients with Advanced Ovarian Cancer Utilizing PARP Inhibitor Second-Line Maintenance Therapy vs Active Surveillance
Alisha Monnette, PhD, MPH
Real-world (RW) Treatment Patterns and Clinical Outcomes for Chemotherapy-Based Regimens in First Line (1L) MSI-H/dMMR Metastatic Colorectal Cancer (mCRC)
Anupama Vasudevan, PhD
POSTER
PODIUM
ABSTRACT PUBLICATIONS
Research Acceptances
Monday, June 6, 2022 | 3 - 6 PM
Impact of Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network’s MYLUNG Consortium
Beth Koselke, PharmD, BCOP
Monday, June 6, 2022 | 8 - 11 AM | Poster #116
Predictors of Biomarker Testing Among Patients (pts) with Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Nicholas Robert, MD
Learn More
ABSTRACT PUBLICATIONS
POSTER
PODIUM
ABSTRACT PUBLICATIONS
POSTER
PODIUM
Philip K. Chan, PhD, MS
Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network
April 2022
Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network
January 2022
MYLUNG Consortium: Molecularly Informed Lung Cancer Treatment in
a Community Cancer Network. Pragmatic Prospective RWR Study
September 2022
Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices.
June 2022
More...
Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products (FDA-2021-D-1214)
Data Standards for Drug and Biological Submissions Containing Real- World-Data: Guidance for Industry (FDA-2021-D-0548)
Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products Guidance for Industry (FDA-2021-D-1146)
Re: Real-World Data: Assessing Electronic Health Records (EHRs) and Medical Claims Data to Support Regulatory Decision-Making for Drugs and Biological Products (FDA-2020-D-2307)
Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network
Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network
MYLUNG Consortium: Molecularly Informed Lung Cancer Treatment in
a Community Cancer Network. Pragmatic Prospective RWR Study
Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices.
More...
Philip K. Chan, PhD, MS
Sr. Observational Researcher
Expertise
Dr. Chan is an HEOR professional with a demonstrated history of working in the information technology and services industry. He has expertise in data collection, healthcare analytics, and statistics.
Education & Experience
Dr. Chan received his PhD in Epidemiology and master’s degree in Biostatistics from Case Western Reserve University. Before joining Ontada, Dr. Chan held various positions at IBM supporting the use of EHR and claims data for HEOR research.
Alisha Monnette, PhD, MPH
Sr. Observational Researcher
Expertise
Dr. Monnette is an HEOR professional who specializes in RWE oncology research, leading and overseeing studies in collaboration with pharmaceutical industry and academic partners to disseminate findings for research and regulatory purposes. She has co-authored over 20 publications that have explored health services utilization and health economics outcomes research.
Education & Experience
Dr. Monnette received her PhD in Health Policy and Management from Tulane University School of Public Health and Tropical Medicine. She holds a Master’s in Public Health from the University of Miami (FL). She has extensive experience leading large RWE and HEOR studies.
Learn more >
Learn more >
Learn more >
Additional
MYLUNG Consortium Research
PRIVACY NOTICE
Research Acceptances
Get in Touch
Ontada
Learn More
Learn More
Learn More
Learn More
Learn More
